S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
NASDAQ:FBIO

Fortress Biotech - FBIO Competitors

$0.75
0.00 (-0.58%)
(As of 03/27/2023 04:00 PM ET)
Add
Compare
Today's Range
$0.74
$0.80
50-Day Range
$0.66
$1.10
52-Week Range
$0.48
$1.53
Volume
443,353 shs
Average Volume
657,997 shs
Market Capitalization
$85.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

FBIO vs. VSTM, BOLT, SPPI, MACK, XOMA, RIGL, XLO, VBIV, RVPH, and VTVT

Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Verastem (VSTM), Bolt Biotherapeutics (BOLT), Spectrum Pharmaceuticals (SPPI), Merrimack Pharmaceuticals (MACK), XOMA (XOMA), Rigel Pharmaceuticals (RIGL), Xilio Therapeutics (XLO), VBI Vaccines (VBIV), Reviva Pharmaceuticals (RVPH), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical preparations" industry.

Fortress Biotech vs.

Verastem (NASDAQ:VSTM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Fortress Biotech has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verastem$2.60 million32.03-$73.81 million-$0.38-1.09
Fortress Biotech$68.79 million1.24-$64.70 million-$1.05-0.71

Verastem has a net margin of 0.00% compared to Fortress Biotech's net margin of -117.49%. Fortress Biotech's return on equity of -54.56% beat Verastem's return on equity.

Company Net Margins Return on Equity Return on Assets
Verastem N/A -124.62% -69.85%
Fortress Biotech -117.49% -54.56% -24.45%

Verastem has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.

Verastem currently has a consensus price target of $4.25, suggesting a potential upside of 924.10%. Fortress Biotech has a consensus price target of $6.00, suggesting a potential upside of 700.00%. Given Verastem's higher possible upside, research analysts plainly believe Verastem is more favorable than Fortress Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verastem
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Fortress Biotech
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Verastem had 6 more articles in the media than Fortress Biotech. MarketBeat recorded 12 mentions for Verastem and 6 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.05 beat Verastem's score of -0.03 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Verastem
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fortress Biotech
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Verastem received 269 more outperform votes than Fortress Biotech when rated by MarketBeat users. However, 67.38% of users gave Fortress Biotech an outperform vote while only 66.55% of users gave Verastem an outperform vote.

CompanyUnderperformOutperform
VerastemOutperform Votes
585
66.55%
Underperform Votes
294
33.45%
Fortress BiotechOutperform Votes
316
67.38%
Underperform Votes
153
32.62%

60.6% of Verastem shares are owned by institutional investors. Comparatively, 27.9% of Fortress Biotech shares are owned by institutional investors. 2.9% of Verastem shares are owned by company insiders. Comparatively, 26.3% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Fortress Biotech beats Verastem on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBIO vs. The Competition

MetricFortress BiotechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$85.08M$5.53B$4.31B$5.85B
Dividend YieldN/A2.60%5.98%4.51%
P/E Ratio-0.714.6497.5712.31
Price / Sales1.24283.173,427.7557.00
Price / CashN/A20.4727.06103.15
Price / Book0.334.264.494.98
Net Income-$64.70M$184.61M$114.18M$190.13M
7 Day Performance5.59%-0.27%1.48%1.97%
1 Month PerformanceN/A-8.57%-5.29%-4.83%
1 Year Performance-44.03%-12.88%-15.53%-17.62%

Fortress Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VSTM
Verastem
2.0053 of 5 stars
$0.43
-4.4%
$4.25
+888.4%
-63.2%$86.29M$2.60M-1.1348Analyst Report
Short Interest ↑
BOLT
Bolt Biotherapeutics
2.0371 of 5 stars
$1.42
-2.7%
$7.00
+393.0%
-52.8%$53.48M$1.26M-0.5591Upcoming Earnings
SPPI
Spectrum Pharmaceuticals
2.3114 of 5 stars
$0.73
-12.0%
$2.44
+233.9%
-49.6%$148.34MN/A-1.14163Analyst Revision
Gap Up
High Trading Volume
MACK
Merrimack Pharmaceuticals
1.4007 of 5 stars
$11.73
+1.5%
N/A+94.0%$167.21MN/A-106.64426
XOMA
XOMA
2.0833 of 5 stars
$19.44
-0.2%
$69.00
+254.9%
-22.1%$222.80M$6.03M-9.8712
RIGL
Rigel Pharmaceuticals
2.224 of 5 stars
$1.34
-4.3%
$4.21
+214.1%
-60.7%$232.69M$120.24M-3.94165
XLO
Xilio Therapeutics
2.0247 of 5 stars
$3.00
+3.1%
$11.25
+275.0%
-56.0%$82.41MN/A-0.9374Short Interest ↑
VBIV
VBI Vaccines
1.8158 of 5 stars
$0.32
+3.2%
$2.00
+524.8%
-81.4%$82.67M$1.08M-0.73149Positive News
RVPH
Reviva Pharmaceuticals
1.9271 of 5 stars
$3.97
-2.0%
$12.00
+202.3%
+84.5%$81.13MN/A-3.645Upcoming Earnings
Positive News
VTVT
vTv Therapeutics
1.4343 of 5 stars
$0.77
flat
$4.00
+417.7%
+9.6%$80.80M$2.02M-3.099Analyst Report
Positive News
This page (NASDAQ:FBIO) was last updated on 3/27/2023 by MarketBeat.com Staff